Table 2

Comparison of baseline clinical and echocardiographic characteristics between the narrow QRS subgroup and the original PROSPECT study population14

VariableNarrow QRS (n=41)PROSPECT (n=426)p Value
Age, yrs64±1368±110.031
Gender, male29 (71)302 (71)1.00
NYHA functional class III39 (95)410 (96)0.67
Ischemic aetiology20 (49)231 (54)0.52
Diabetes10 (24)140 (33)0.30
History of atrial fibrillation4 (10)84 (20)0.14
History of ventricular tachycardia11 (27)115 (27)1.00
QRS duration, ms108±14163±22<0.0001
Left bundle branch block10 (24)327 (77)<0.0001
Medication:
Diuretics38 (93)355 (83)0.18
ACE-inhibitors35 (85)390 (92)0.25
B-blockers30 (73)361 (85)0.07
Spironolactone17 (41)169 (40)0.87
LV end-diastolic diameter, mm67±1064±110.24
LV end-systolic diameter, mm58±956±120.26
LV end-diastolic volume, ml241±92230±990.51
LV end-systolic volume, ml174±77168±890.68
LV ejection fraction, %25±624±70.27
Myocardial performance index0.79±0.240.89±0.330.030
Mitral regurgitation, %21±2019±170.64
  • ACE, angiotensin converting enzyme; LV, left ventricular; NYHA, New York Heart Association.